Hope Bancorp Declares Quarterly Cash Dividend of $0.14 Per Share
About Hope Bancorp, Inc.
Hope Bancorp, Inc. (NASDAQ: HOPE) is the holding company of Bank of Hope, the first and only super regional Korean American bank in the United States with $17.05 billion in total assets as of December 31, 2024. Headquartered in Los Angeles and serving a multi-ethnic population of customers across the nation, the Bank provides a full suite of commercial, corporate and consumer loans, including commercial and commercial real estate lending, SBA lending, residential mortgage and other consumer lending; deposit and fee-based products and services; international trade financing; and cash management services, foreign currency exchange solutions, and interest rate derivative products, among others. Bank of Hope operates 46 full-service branches in California, Washington, Texas, Illinois, New York, New Jersey, Alabama, and Georgia. The Bank also operates SBA loan production offices, commercial loan production offices, and residential mortgage loan production offices in the United States; and a representative office in Seoul, Korea. Bank of Hope is a California-chartered bank, and its deposits are insured by the FDIC to the extent provided by law. Bank of Hope is an Equal Opportunity Lender. For additional information, please go to www.bankofhope.com. By including the foregoing website address link, the Company does not intend to and shall not be deemed to incorporate by reference any material contained or accessible therein.
213-235-3235
[email protected] Yang
213-251-2219
SOURCE: Hope Bancorp, Inc.
Copyright Business Wire 2025.
PUB: 01/27/2025 07:32 AM/DISC: 01/27/2025 07:32 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
DexCom Stock: Analyst Estimates & Ratings
DexCom, Inc. (DXCM), headquartered in San Diego, California, is a global leader in the development and manufacturing of continuous glucose monitoring (CGM) systems. The company primarily serves people with diabetes by offering advanced, real-time monitoring solutions that track glucose levels, enabling more precise and proactive diabetes management. DexCom's flagship products include the DexCom G6 and G7 systems, which provide users with continuous, non-invasive data for better glucose control. Beyond diabetes, DexCom is expanding into areas like diabetes prevention and insulin dosing optimization, positioning itself as a key player in the evolving healthcare and medical device sectors. The company has a market capitalization of $31.36 billion. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Shares of this medical device company have gained 12.6% over the past 52 weeks, underperforming the broader S&P 500 Index ($SPX), which has gained 19% over the same period. This year, the stock has gained a modest 2.8%, while the S&P 500 index is up almost 10% year-to-date (YTD). To put this into perspective, we compare with the sector-specific iShares U.S. Medical Devices ETF (IHI). The ETF's gains have more or less aligned with DexCom's, rising by 10.3% over the past 52 weeks and 5.9% on a YTD basis. Despite DexCom's strong second-quarter results on Jul. 30, the market's reaction was not positive, as the stock price dropped a notable 9.3% the very next trading session. The company's revenue increased 15.2% year-over-year (YOY) to $1.16 billion. DexCom also received FDA clearance for the DexCom G7 15 Day CGM System. Its adjusted EPS increased 11.6% YOY to $0.48, surpassing the $0.45 figure expected by Wall Street analysts. For the fiscal year 2025, ending this December, Wall Street analysts expect DexCom's bottom line to grow by 25% YOY to $2.05 per share on a diluted basis. The company has a mixed history of surpassing consensus estimates, topping them in two of the trailing four quarters and missing them on two other occasions. Among the 25 analysts covering DexCom's stock, the consensus is a 'Strong Buy.' That's based on 20 'Strong Buy' ratings, one 'Moderate Buy' rating, and four 'Holds.' The current configuration of the ratings is slightly more bullish than two months ago, when the stock had 19 'Strong Buy' ratings. Reflecting a stable market outlook for the company, Canaccord Genuity analyst William Plovanic maintained a 'Buy' rating on the stock this month, while keeping the price target at $106. On July 31, Raymond James analyst Jayson Bedford maintained a "Strong Buy" rating, with the price target on the stock raised from $99 to $102. DexCom's mean price target of $102.60 indicates a premium of 28.3% from the current market prices. The Street-high price target of $125 implies a potential upside of 56.3%. On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Tilray Eyes Reverse Stock Split As Nasdaq Listing Compliance Pressure Mounts
Tilray Brands, Inc. (NASDAQ:TLRY) shares slipped Thursday after the company said it is seeking more time from Nasdaq to restore compliance with the exchange's continued listing rules tied to its per-share price. The cannabis and consumer packaged goods firm also signaled it may pursue a shareholder-approved reverse stock split if needed to keep its listing intact. Tilray has filed a request to extend the window to regain eligibility under Nasdaq standards and is evaluating several capital-structure options, including a potential reverse split, to ensure move aims to protect its listing while the board reviews next steps. Chief Executive Irwin Simon said that recent trading strength has followed President Trump's review of cannabis rescheduling and reflects confidence in Tilray's diversified platform. Tilray's trading levels have appreciated in recent weeks following President Trump's review of cannabis rescheduling. Tilray also highlighted momentum in its medical business in Europe. Its medical unit's wholly owned subsidiary FL Group S.R.L. formed a new distribution alliance in Italy with L. Molteni & C. dei Alitti Società di Esercizio S.p.A. to broaden access to cannabis extracts for patients, reflecting growing demand and new partnership opportunities across the region. The extension request underscores Tilray's effort to maintain its Nasdaq listing while navigating market volatility and evolving U.S. policy signals around cannabis. A reverse split remains one option to rectify minimum bid price thresholds, as the company balances capital-market requirements with expansion in medical and wellness categories. Price Action: TLRY shares are trading lower by 6.12% to $1.170 at last check Thursday. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? TILRAY BRANDS (TLRY): Free Stock Analysis Report This article Tilray Eyes Reverse Stock Split As Nasdaq Listing Compliance Pressure Mounts originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
LA28 making Olympics history with first sale of venue naming rights for Games
Venues for the 2028 Olympics and Paralympics will be permitted to sell naming rights, a first in the Games' storied history. LA28, the organizing committee for the upcoming Summer Olympics in Los Angeles, and the International Olympic Committee (IOC) struck an agreement, which alleviates logistical headaches, cuts costs for the city and helps cover the budget for the Games but also continues the commercialization of an event the IOC has tried to protect over the years from corporate influence. It's important to note, however, that the field of play will remain free of visible advertising. 'Our job is to push and our job is to do what's best for the Olympics in Los Angeles,' LA28 chairman Casey Wasserman told the Los Angeles Times. 'Our job in those conversations [with the IOC] was to explain why this was more than just about money. It was about experience and value and opportunity.' Well-known venues such as SoFi Stadium and Arena will no longer have to adopt generic nicknames or remove existing signage for the Games. Notably, SoFi will host the opening and closing ceremonies along with swimming, and Arena will host gymnastics and boxing in 2028. "People know 'Crypto' as 'Crypto,' they don't know it as 'the gymnastics arena downtown,'' Wasserman said, via The Associated Press, when discussing Arena, the full-time home of the Los Angeles Lakers. For those venues with pre-existing sponsorship names, the companies that currently own naming rights can retain those for the Olympics by signing on as a founding-level partner, according to the LA Times. If they don't sign on, those venues will be renamed without a sponsor, per the LA Times' report. LA28 announced in a release Thursday that up to 19 temporary venues can carry naming rights, with members of The Olympic Partners program receiving first bidding opportunities. Contracts are in place for two of them already: Comcast Squash Center at Universal Studios and Honda Center, the latter of which will keep its name for the Olympic volleyball competition in Anaheim. The LA Coliseum, Rose Bowl and Dodger Stadium are not included in this new naming rights arrangement, according to the AP. But the revenue raised from these deals will prove critical in backing what LA28 describes as a privately-funded Games.
